‌

US Patent 8362068 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Patent 8362068 was granted and assigned to Idenix Pharmaceuticals on January, 2013 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Current Assignee

Idenix Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

January 29, 2013

Patent Application Number

12972254

Date Filed

December 17, 2010

Patent Citations Received

US Patent 11707479 Combination formulation of two antiviral compounds

0

US Patent 12084473 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

0

US Patent 12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

0

US Patent 11707480 Highly active compounds against COVID-19

0

US Patent 11975016 2′-substituted-N

0

Patent Primary Examiner

Patent abstract

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8362068 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool